Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy

Ionis Pharmaceuticals (IONS) PT Raised to $36 at Leerink Partners

Leerink Partners analyst Michael Schmidt raised his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $36.00 (from $26.00) after the company announced that nusinersen, its antisense drug in development for treatment of spinal muscular atrophy (SMA) met the primary endpoint at the interim analysis of the Ph III trial "ENDEAR", which is evaluating the drug's effect in infantile-onset Type I SMA.. The firm maintained an Market... More

Biogen (BIIB) PT Raised to $367 at Leerink Partners

Leerink Partners analyst Geoffrey Porges raised his price target on Biogen (NASDAQ: BIIB) to $367.00 (from $360.00) but maintained an Market Perform following positive nusinersen data.

Porges commend, "This morning Biogen and Ionis (MP) announced that ENDEAR, a phase 3 study of nusinersen in the treatment of infant-onset (Type I) spinal muscular atrophy (SMA), met its primary pre-specified endpoints following an interim analysis. In a conference call following the... More

Baird Incrementally Positive on Biogen (BIIB) Nusinersen Data; PT to $284

Baird analyst Brian Skorney bumped his price target on Biogen (NASDAQ: BIIB) to $284.00 (from $268.00) but lefts his Neutral rating, saying they are incrementally positive on nusinersen interim Phase 3 results.

Skorney commented, "Results are in, earlier than expected, and nusinersen appears to... More

Stifel Affirms Biogen at 'Hold' Following Strong Nusinersen Phase 3 Data

Stifel affirms Biogen (Nasdaq: BIIB) at Hold after the company and Ionis Pharmaceuticals announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen in infantile-onset (consistent with... More

Biogen (BIIB) PT Raised to $304 at BMO Capital

BMO Capital analyst M. Ian Somaiya raised his price target on Biogen (NASDAQ: BIIB) to $304.00 (from $286.00) following announcement that nusinersen hit the motor function primary endpoint in an interim analysis from the P3 trial, but maintained a Market Perform rating.

Somaiya... More

Ionis Pharmaceuticals (IONS) PT Raised to $40 at BMO Capital

BMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $40.00 (from $25.00) after positive interim data from the Phase III ENDEAR study for infant-onset SMA and Biogen exercising its option to license Nusinersen but maintained a Market Perform... More

Ionis Pharmaceuticals (IONS) PT Raised to $64 at Needham & Company as ENDEAR Study Halted Early for Efficacy

Needham & Company analyst Chad Messer reiterated a Buy rating and lifted its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $64.00 (from $55.00) after the company and Biogen announced the pivotal ENDEAR study of nusinersen in infants with spinal muscular atrophy (SMA) met its primary endpoint... More